Search
Sitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnSitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsOxomemazine
go.drugbank.com/drugs/DB13820InvestigationalOxomemazine is a phenothiazine derivative.
Categories: Heterocyclic Compounds, 3-RingAvasopasem manganese
go.drugbank.com/drugs/DB16354InvestigationalAvasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.
ATN-161
go.drugbank.com/drugs/DB05491InvestigationalATN-161 is a non-RGD based integrin binding peptide targeting alpha-5 beta-1 and alpha-v beta-3. … Since the expression of alpha(5)beta(1) integrin by cancer cells and the role of this molecule in tumor angiogenesis is similar across a range of different cancers, the therapeutic benefit of ATN-161 is
DG051
go.drugbank.com/drugs/DB05177ExperimentalDG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
Zofin
go.drugbank.com/drugs/DB16519InvestigationalZofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the
GS-441524
go.drugbank.com/drugs/DB15686Investigational[L13775] _In vitro_ studies of GS-441524 have determined it has a higher EC<sub>50</sub> than remdesivir against a number of viruses, meaning GS-441524 is less potent. … GS-441524 is an adenosine nucleotide analog antiviral, similar to [remdesivir].[A203057,L13239] This molecule was patented in 2009.
Categories: Heterocyclic Compounds, 2-RingXL228
go.drugbank.com/drugs/DB05184InvestigationalXL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation